Human mesenchymal stromal cells (hMSCs) show great potential for clinical and experimental use due to their capacity to self-renew and differentiate into multiple mesenchymal lineages. However, disadvantages of primary cultures of hMSCs are the limited in vitro lifespan, and the variable properties of cells from different donors and over time in culture. In this article, we describe the generation of a telomerase-immortalized nontumorigenic human bone marrow-derived stromal mesenchymal cell line, and its detailed characterization after long-term culturing (up to 155 population doublings). The resulting cell line, iMSC#3, maintained a fibroblast-like phenotype comparable to early passages of primary hMSCs, and showed no major differences from hMSCs regarding surface marker expression. Furthermore, iMSC#3 had a normal karyotype, and high-resolution array comparative genomic hybridization confirmed normal copy numbers. The gene expression profiles of immortalized and primary hMSCs were also similar, whereas the corresponding DNA methylation profiles were more diverse. The cells also had proliferation characteristics comparable to primary hMSCs and maintained the capacity to differentiate into osteoblasts and adipocytes. A detailed characterization of the mRNA and microRNA transcriptomes during adipocyte differentiation also showed that the iMSC#3 recapitulates this process at the molecular level. In summary, the immortalized mesenchymal cells represent a valuable model system that can be used for studies of candidate genes and their role in differentiation or oncogenic transformation, and basic studies of mesenchymal biology.
Get full access to this article
View all access options for this article.
References
1.
FibbeWE and NoortWA. (2003). Mesenchymal stem cells and hematopoietic stem cell transplantation. Ann N Y Acad Sci, 996:235–244.
2.
GrecoSJ, ZhouC, YeJH and RameshwarP. (2007). An interdisciplinary approach and characterization of neuronal cells transdifferentiated from human mesenchymal stem cells. Stem Cells Dev, 16:811–826.
3.
LeeKD, KuoTK, Whang-PengJ, ChungYF, LinCT, et al. (2004). In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 40:1275–1284.
4.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
5.
BoquestAC, ShahdadfarA, FronsdalK, SigurjonssonO, TunheimSH, et al. (2005). Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell, 16:1131–1141.
6.
GhannamS, BouffiC, DjouadF, JorgensenC and NoelD. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther, 1:2
7.
NoortWA, KruisselbrinkAB, in't AnkerPS, KrugerM, van BezooijenRL, et al. (2002). Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol, 30:870–878.
8.
HonmaT, HonmouO, IihoshiS, HaradaK, HoukinK, et al. (2006). Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol, 199:56–66.
9.
HamadaH, KobuneM, NakamuraK, KawanoY, KatoK, et al. (2005). Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci, 96:149–156.
10.
HoughtonJ, StoicovC, NomuraS, RogersAB, CarlsonJ, et al. (2004). Gastric cancer originating from bone marrow-derived cells. Science, 306:1568–1571.
11.
RiggiN, CironiL, ProveroP, SuvaML, KaloulisK, et al. (2005). Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res, 65:11459–11468.
12.
LiuTM, MartinaM, HutmacherDW, HuiJHP, LeeEH, et al. (2007). Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells, 25:750–760.
13.
BaxterMA, WynnRF, JowittSN, WraithJE, FairbairnLJ, et al. (2004). Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells, 22:675–682.
14.
SimonsenJL, RosadaC, SerakinciN, JustesenJ, StenderupK, et al. (2002). Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol, 20:592–596.
15.
MiharaK, ImaiC, Coustan-SmithE, DomeJS, DominiciM, et al. (2003). Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol, 120:846–849.
16.
KawanoY, KobuneM, YamaguchiM, NakamuraK, ItoY, et al. (2003). Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood, 101:532–540.
17.
KangSK, PutnamL, DufourJ, YlostaloJ, JungJS, et al. (2004). Expression of telomerase extends the lifespan and enhances osteogenic differentiation of adipose tissue-derived stromal cells. Stem Cells, 22:1356–1372.
18.
GongM, BiY, JiangW, ZhangY, ChenL, et al. (2011). Immortalized mesenchymal stem cells: an alternative to primary mesenchymal stem cells in neuronal differentiation and neuroregeneration associated studies. J Cell Biochem, 18:87
19.
AbdallahBM, Haack-SorensenM, BurnsJS, ElsnabB, JakobF, et al. (2005). Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite extensive proliferation. Biochem Biophys Res Commun, 326:527–538.
20.
GaoK, LuYR, WeiLL, LuXF, LiSF, et al. (2008). Immortalization of mesenchymal stem cells from bone marrow of rhesus monkey by transfection with human telomerase reverse transcriptase gene. Transplant Proc, 40:634–637.
21.
LiuTM, NgWM, TanHS, VinithaD, YangZ, et al. (2013). Molecular basis of immortalization of human mesenchymal stem cells by combination of p53 knockdown and human telomerase reverse transcriptase overexpression. Stem Cells Dev, 22:268–278.
22.
SkarnM, NamlosHM, NoordhuisP, WangMY, Meza-ZepedaLA, et al. (2012). Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222. Stem Cells Dev, 21:873–883.
23.
CounterCM, MeyersonM, EatonEN, EllisenLW, CaddleSD, et al. (1998). Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene, 16:1217–1222.
24.
KinsellaTM and NolanGP. (1996). Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther, 7:1405–1413.
25.
OchmanH, GerberAS and HartlDL. (1988) Genetic applications of an inverse polymerase chain reaction. Genetics, 120:621–623.
26.
ShafferL, SlovakM and CampbellL. (2009). ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet, 126:603–604.
27.
KresseSH, RydbeckH, SkårnM, NamløsHM, Barragan-PolaniaAH, et al. (2012). Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One, 7:e48262
28.
SerakinciN, GuldbergP, BurnsJS, AbdallahB, SchrodderH, et al. (2004). Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene, 23:5095–5098.
29.
in't AnkerPS, NoortWA, ScherjonSA, Kleijburg-van der KeurC, KruisselbrinkAB, et al. (2003). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica, 88:845–852.
30.
GregoryCA, Grady GunnW, PeisterA and ProckopDJ. (2004). An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem, 329:77–84.
31.
CampeauE, RuhlVE, RodierF, SmithCL, RahmbergBL, et al. (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One, 4:e6529
32.
BookoutAL, CumminsCL, MangelsdorfDJ, PesolaJM and KramerMF. (2001). High-Throughput Real-Time Quantitative Reverse Transcription PCR. Current Protocols in Molecular Biology. John Wiley & Sons, Inc., Hoboken, NJ.
33.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
34.
OskowitzAZ, LuJ, PenfornisP, YlostaloJ, McBrideJ, et al. (2008). Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci U S A, 105:18372–18377.
35.
BaeS, AhnJH, ParkCW, SonHK, KimKS, et al. (2009). Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts. Cell Tissue Res, 335:565–573.
36.
WuL, LeijtenJC, GeorgiN, PostJN, van BlitterswijkCA, et al. (2011). Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. Tissue Eng, 17:1425–1436.
37.
PartridgeKA and OreffoRO. (2004). Gene delivery in bone tissue engineering: progress and prospects using viral and nonviral strategies. Tissue Eng, 10:295–307.
38.
SimpsonAJG, CaballeroOL, JungbluthA, ChenY-T and OldLJ. (2005). Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 5:615–625.
39.
KularRK, YehielyF, KotloKU, CilensekZM, BediR, et al. (2009). GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res, 29:645–655.
40.
GjerstorffMF, RösnerHI, PedersenCB, GreveKBV, SchmidtS, et al. (2012). GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL). PLoS One, 7:e45819
41.
YangB, O'HerrinS, WuJ, Reagan-ShawS, MaY, et al. (2007). Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol, 127:267–275.
42.
MoriT, KiyonoT, ImabayashiH, TakedaY, TsuchiyaK, et al. (2005). Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol, 25:5183–5195.
43.
OkamotoT, AoyamaT, NakayamaT, NakamataT, HosakaT, et al. (2002). Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun, 295:354–361.
44.
BorkS, PfisterS, WittH, HornP, KornB, et al. (2010). DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell, 9:54–63.
45.
ChoiMR, InYH, ParkJ, ParkT, JungKH, et al. (2012). Genome-scale DNA methylation pattern profiling of human bone marrow mesenchymal stem cells in long-term culture. Exp Mol Med, 44:503–512.
46.
BrønnumH, AndersenDC, SchneiderM, SandbergMB, EskildsenT, et al. (2013). miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving programmed cell death 4 and sprouty-1. PLoS One, 8:e56280
TenstadE, TourovskaiaA, FolchA, MyklebostO and RianE. (2010). Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device. Lab Chip, 10:1401–1409.
49.
Døsen-DahlG, MuntheE, NygrenMK, StubberudH, HystadME, et al. (2008). Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: Role of TGFβ/BMP-6 and TIEG1 in chemotherapy escape. Int J Cancer, 123:2759–2766.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
